LAU-7b for Lung Inflammation in Cystic Fibrosis

LAU-7b is an oral form of the retinoid fenretinide, being developed by Laurent Pharmaceuticals. Retinoids are a group of compounds related to vitamin A. Fenretinide may help reduce the inflammatory response in the lungs of people with cystic fibrosis (CF).1 Administrated as a once-a-day, solid dose of fenretinide, LAU-7b is designed to correct the defective metabolism and modulate chronic inflammation due to the genetic defect that causes cystic fibrosis.2

How LAU-7b works

Arachidonic acid (AA) and docosahexanoic acid (DHA) are two essential fatty acids that play a key role in maintaining an effective immune-inflammatory response. The genetic defect that causes CF leads to exaggerated AA-mediated inflammation and low DHA-mediated resolution, causing lung infection and local tissue damage.

LAU-7b works by correcting the defective metabolism of AA and DHA, and controlling chronic inflammation via what the company’s calls “a pro-resolving mechanism” maintained by a relation to the expression of the CF genetic defect.

Resolution of inflammation is a new approach that uses the body’s own ability to modulate inflammatory responses, with the goal of addressing inflammation without inducing immunosuppression.

LAU-7b studies

LAU-7b was tested in people with cystic fibrosis in a dose-ascending Phase 1b (NCT02141958) trial, and demonstrated good safety and tolerability, as well as promising pharmacokinetic and pharmacodynamic properties.

The trial was a single-center, double-blind, and placebo-controlled study  of three increasing oral doses of LAU-7b compared to placebo. Treatment with up to 300 mg of LAU-7b for 21 days was found to be safe and well-tolerated by adults with CF, and achieved the proposed target plasma concentration in all participants at that dose level. LAU-7b normalized the blood levels of AA and DHA in almost all of the participants, leading to a more anti-inflammatory pattern in the patients, especially during pulmonary exacerbation, Laurent reported on its website.

A Phase 2 study in adults with CF, using the 300 mg dose level, is currently being prepared for the United States and Canada.4

Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  1. https://www.cff.org/Trials/Pipeline/details/10137/LAU-7b
  2. https://cysticfibrosisnewstoday.com/Laurent+Pharmaceuticals+Awarded+%243M+to+Initiate+Phase+2+Study+of+Oral+CF+Therapy
  3. http://www.laurentpharma.com/news/62-laurent-pharmaceuticals-receives-us-3m-development-award-from-cystic-fibrosis-foundation-therapeutics.html
  4. http://www.laurentpharma.com/development.html

Featured Column

Don’t Overlook Emotional Wellness When Dealing With Chronic Illness

A banner for Lara's column, depicting a car on a road trip winding through a forest.
Living with a chronic illness can affect emotional wellness, writes columnist Lara Govendo, who offers up some ideas for managing both.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.